Grifols, S.A. Share Price & Technical Analysis

GRFS · $7.98 (-1.60%)

Healthcare / Drug Manufacturers - General

AI Score 42 · Weak

$7.98

-1.60%

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, i

Price chart

Seasonality

May has 4 positive and 1 negative years (last 5 years shown)

-2% return in May, 13% avg return in past 3 year May month.

-16% return in 2026, 18% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
26-2%-2%-10%1%-2%-16%
25-8%25%-15%-3%19%7%20%-6%2%-5%-5%7%38%
24-29%-7%-4%-4%13%-14%15%21%-5%-2%-20%7%-30%
236%-5%-13%4%8%11%20%-10%-4%-12%20%21%45%
224%6%-9%-10%18%-8%-24%-12%-18%2%23%4%-25%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 42/100

Weak · Downtrend · Neutral

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$5.15B

P/E ratio

10.81

52W high

$11.14

52W low

$7.39

Volume

3,79,991

Beta

1.17

Related stocks in Healthcare

Frequently asked questions

What is Grifols, S.A. share price today?
Grifols, S.A. (GRFS) last traded around $7.98 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does GRFS have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GRFS. Download the app for real-time alerts.
How can I analyze Grifols, S.A. stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro